Drug Profile
Research programme: allergy immunotherapies - Ayala Pharmaceuticals/Karolinska Institute
Latest Information Update: 23 Jan 2023
Price :
$50
*
At a glance
- Originator Advaxis
- Developer Ayala Pharmaceuticals; Karolinska Institute
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypersensitivity